Innate Pharma (IPHYF) Capital Expenditures (2019 - 2024)
Historic Capital Expenditures for Innate Pharma (IPHYF) over the last 6 years, with Q4 2024 value amounting to -$417820.8.
- Innate Pharma's Capital Expenditures fell 1063.56% to -$417820.8 in Q4 2024 from the same period last year, while for Dec 2024 it was -$1.1 million, marking a year-over-year increase of 3373.14%. This contributed to the annual value of $417820.8 for FY2024, which is 1063.56% up from last year.
- According to the latest figures from Q4 2024, Innate Pharma's Capital Expenditures is -$417820.8, which was down 1063.56% from -$377654.9 recorded in Q4 2023.
- In the past 5 years, Innate Pharma's Capital Expenditures ranged from a high of -$289025.2 in Q2 2021 and a low of -$1.1 million during Q4 2020
- Its 5-year average for Capital Expenditures is -$573147.2, with a median of -$448163.8 in 2022.
- Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 5176.44% in 2021, then plummeted by 5506.05% in 2022.
- Over the past 5 years, Innate Pharma's Capital Expenditures (Quarter) stood at -$1.1 million in 2020, then increased by 1.73% to -$1.1 million in 2021, then soared by 48.64% to -$545832.3 in 2022, then soared by 30.81% to -$377654.9 in 2023, then decreased by 10.64% to -$417820.8 in 2024.
- Its Capital Expenditures stands at -$417820.8 for Q4 2024, versus -$377654.9 for Q4 2023 and -$336477.6 for Q2 2023.